Introduction
The cost of specialty prescription medications can add another concern for people already managing a chronic inflammatory condition, a serious illness, or a condition such as severe alopecia areata. Olumiant is a specialty oral medication used for several FDA-approved conditions, and the amount a patient pays can vary considerably depending on insurance coverage, dosage, pharmacy benefits, and other factors.
The medication contains baricitinib, a JAK1 and JAK2 inhibitor that works by reducing signaling involved in certain inflammatory and immune responses. Its FDA-approved uses include rheumatoid arthritis, hospitalized adult COVID-19 requiring specified respiratory support, and severe alopecia areata.
Prescription Hope provides medication assistance support for eligible patients seeking more affordable access to prescription medications. Understanding available patient assistance options can be an important step for patients who are concerned about their medication costs.
What Is the Olumiant Patient Assistance Program?
Understanding Prescription Assistance
Many Americans struggle to afford their monthly medication costs. Those taking brand-name medications and paying out-of-pocket may feel a financial burden.
To help alleviate patients’ difficulties with high and rising brand-name medication costs, pharmaceutical manufacturers offer patient assistance programs.
These programs, such as the Olumiant patient assistance program, provide qualified patients with access to their brand-name medication at affordable rates.
However, patient assistance programs have been known to include complex and sometimes frustrating application processes.
How Expert Advocates Help Make Olumiant More Affordable
Personalized Medication Assistance
Getting prescription assistance for Olumiant does not have to be painful.
Prescription Hope helps qualified patients access Olumiant at an affordable rate through the Olumiant patient assistance program.
Our team of patient advocates works on your behalf to complete forms, collect documents and signatures, coordinate with healthcare providers and manufacturers, and much more.
Ongoing Patient Support
Not only does Prescription Hope support patients throughout the application process, but our specialty medication support services continue long after a patient is approved.
Our medication access specialists manage administrative tasks associated with enrollment status.
We handle refill scheduling, document updates, issue resolution, program monitoring, yearly renewals, and more.
Olumiant Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Navigating Treatment Costs
Dealing with specialty medication treatment cost and general specialty drug costs can be a massive financial burden for patients.
KFF reports that “Just under half of U.S. adults say it is difficult to afford health care costs,” and that “About four in ten (43%) U.S. adults say they have not taken their medication prescribed in the past year due to costs.”
Prescription Hope’s service rate is a simple $70.00 per month, per medication. Our patients never have to worry about hidden fees, add-ons, or medication costs.
And if we cannot help you save on your monthly medication costs, then you pay nothing!
Olumiant Patient Assistance Eligibility
General Eligibility Requirements
Understanding Olumiant patient assistance eligibility specifics is best done by enrolling with Prescription Hope.
However, it is useful to understand the general categories used to determine qualification criteria. Some of these categories include:
Income: All programs require an income that falls within a specific range. Each program differs in the required range.
Insurance: Each program maintains a selected insurance coverage status. Some programs require a qualified patient to have no coverage, while others may allow some form of coverage.
Prescription: Qualified patients must have a valid and current prescription for the medication they wish to apply for.
Residency: All qualified patients must be legal U.S. residents.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Those looking for how to apply for brand-name medication assistance can enroll with Prescription Hope risk-free. Our enrollment process takes 6 simple steps:
- Submit Information: It only takes a few minutes to complete our online enrollment form.
- Advocate Contact: Once we receive your enrollment form, a patient advocate will contact you within 1-2 business days.
- Document Collection: After a quick prequalification, our team collects all needed documents for your application.
- Provider Coordination: We also collect all signatures from healthcare providers required by your application.
- Program Submission: Once everything is in order, we submit your application to the manufacturer. Our team continues to coordinate with the manufacturer throughout the processing stage.
- Medication Delivery: Following approval, patients typically receive their medication within 2 weeks. All medications ship directly from the manufacturer to a qualified patient’s door or doctor’s office.
Understanding Olumiant
How Olumiant Works
Olumiant contains baricitinib, an oral medication that inhibits the activity of JAK1 and JAK2.
JAK enzymes help transmit signals from certain cytokines and growth factors involved in inflammation and immune-system activity. By inhibiting JAK1 and JAK2, baricitinib reduces signaling involved in abnormal inflammatory and immune responses.
This mechanism is relevant to each of Olumiant’s FDA-approved uses, although the specific inflammatory and immune pathways involved can differ between rheumatoid arthritis, COVID-19, and severe alopecia areata.
In rheumatoid arthritis, reducing inflammatory signaling can help decrease disease activity and associated symptoms. In severe alopecia areata, modifying immune-system activity can help promote scalp hair regrowth. In hospitalized adults with COVID-19 requiring specified respiratory support, it can help modulate inflammatory responses associated with the disease.
This medication is administered orally as a tablet and may be taken with or without food.
What Conditions Does Olumiant Treat?
Olumiant is FDA-approved for three uses.
For moderately to severely active rheumatoid arthritis, it is indicated for adults who have had an inadequate response to one or more TNF blockers. It may be used alone or with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).
Olumiant is also FDA-approved for COVID-19 in hospitalized adults who require supplemental oxygen, non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This is an FDA-approved indication and should not be described only as the medication’s former Emergency Use Authorization.
For severe alopecia areata, Olumiant is indicated for adults with severe disease. The FDA approved this indication in 2022, making it the first FDA-approved systemic treatment specifically indicated for severe alopecia areata.
It is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine or cyclosporine.
Benefits of Treatment
For appropriately selected patients, Olumiant provides an oral treatment option that can affect inflammatory and immune signaling through inhibition of JAK1 and JAK2.
For adults with rheumatoid arthritis, Olumiant may reduce inflammation and disease activity and may improve symptoms and physical function.
For adults with severe alopecia areata, Olumiant can reduce excessive immune activity involved in the condition and may promote scalp hair regrowth.
For hospitalized adults with COVID-19 who require the respiratory support specified in the FDA indication, this medication can help modulate inflammatory responses associated with the disease.
Treatment response varies by condition and individual patient. The appropriate dosage and duration of treatment depend on the indication and factors such as kidney function, laboratory results, other medications, and the patient’s overall clinical circumstances.
Important Safety Information and Side Effects
Olumiant carries an FDA Boxed Warning for serious infections, mortality, malignancies, major adverse cardiovascular events (MACE), and thrombosis. These are important risks associated with Olumiant and the JAK inhibitor class.
The FDA’s boxed warning concerning mortality, malignancy, MACE, and thrombosis incorporates evidence from a large safety study involving another JAK inhibitor compared with TNF blockers in patients with rheumatoid arthritis. These warnings are included in labeling because of potential class-related risks and should not be interpreted as demonstrating an identical magnitude of risk specifically with this medication.
Serious Infections
Olumiant can increase the risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB).
For patients receiving Olumiant for rheumatoid arthritis or severe alopecia areata, healthcare providers should evaluate for TB before treatment and monitor for signs and symptoms during therapy.
Olumiant should generally not be initiated in patients with an active infection unless the healthcare provider determines that treatment is appropriate. Treatment may need to be interrupted if a serious infection develops until the infection is controlled.
Mortality
The FDA Boxed Warning notes a higher rate of all-cause mortality, including sudden cardiovascular death, with another JAK inhibitor compared with TNF blockers in a rheumatoid arthritis population.
This finding contributed to FDA’s requirement for corresponding warnings for Olumiant and other JAK inhibitors in the applicable class.
Malignancies
Malignancies have occurred in patients receiving Olumiant.
The FDA labeling also describes higher rates of lymphoma and lung cancer with another JAK inhibitor compared with TNF blockers in rheumatoid arthritis patients. Patients who currently or previously smoked may have additional risk considerations when treatment with Olumiant is evaluated.
Major Adverse Cardiovascular Events
Major adverse cardiovascular events, or MACE, are included in the FDA Boxed Warning. These events can include cardiovascular death, myocardial infarction, and stroke.
Patients with cardiovascular risk factors should discuss the potential risks and benefits of treatment with their healthcare provider.
Thrombosis
Blood clots have occurred in patients treated with Olumiant. Reported thrombotic events include deep vein thrombosis, pulmonary embolism, and arterial thrombosis.
Patients should seek prompt medical evaluation for symptoms that could indicate a blood clot.
Serious Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Olumiant.
Olumiant should be discontinued if a serious hypersensitivity reaction occurs.
Gastrointestinal Perforations
Gastrointestinal perforations have been reported with Olumiant.
Patients who may have factors that increase this risk should be monitored appropriately, and new or unexplained abdominal symptoms should be evaluated by a healthcare professional.
Hypoglycemia in Patients With Diabetes
The June 2026 FDA labeling includes a specific warning regarding hypoglycemia in patients with diabetes.
Hypoglycemia, including severe hypoglycemia, has been reported following initiation of Olumiant and other JAK inhibitors in patients with diabetes. Healthcare providers may consider increased blood-glucose monitoring when clinically appropriate.
Patients with diabetes should discuss signs or symptoms of low blood sugar with their healthcare provider.
Laboratory Abnormalities
Olumiant can cause laboratory abnormalities involving neutrophil counts, lymphocyte counts, hemoglobin, liver enzymes, and lipid levels.
Healthcare providers may evaluate laboratory values before and during treatment. The FDA prescribing information provides specific thresholds for initiating, interrupting, or modifying treatment based on certain laboratory abnormalities.
Vaccinations
Patients should complete appropriate immunizations before beginning treatment when possible.
Live vaccines should generally be avoided during treatment with this medication.
Pregnancy and Breastfeeding
Available human pregnancy data are insufficient to determine the risk of major birth defects, miscarriage, or other adverse pregnancy outcomes associated with Olumiant. Animal studies have demonstrated developmental effects at sufficiently high exposures, and FDA labeling states that this medication may cause fetal harm.
Patients who are pregnant, planning pregnancy, or who become pregnant while taking Olumiant should discuss treatment with their healthcare provider.
Baricitinib is present in animal milk, but it is not known whether it is present in human milk. Because of the potential for serious adverse reactions in a breastfed infant, the FDA labeling advises patients not to breastfeed during treatment and for 4 days after the final dose.
The current FDA Prescribing Information lists no formal contraindications for this medication. However, significant infection, cardiovascular, thrombotic, malignancy, laboratory, and drug-interaction considerations apply.
Common Side Effects
The side effects associated with Olumiant vary depending on the condition being treated.
For rheumatoid arthritis, commonly reported adverse reactions include upper respiratory tract infections, nausea, herpes simplex infections, and herpes zoster.
In studies involving hospitalized adults with COVID-19, reported adverse reactions and laboratory abnormalities included elevated liver enzymes, increased platelet counts, increased creatine phosphokinase, neutropenia, urinary tract infections, deep vein thrombosis, and pulmonary embolism.
For severe alopecia areata, reported adverse reactions include upper respiratory tract infections, headache, acne, lipid abnormalities, increased creatine phosphokinase, urinary tract infections, elevated liver enzymes, folliculitis, fatigue, lower respiratory tract infections, nausea, genital Candida infections, anemia, neutropenia, abdominal pain, herpes zoster, and weight increase.
The side effects experienced by an individual patient can vary based on the condition being treated, dosage, other medications, and individual health factors.
Access to Multiple Medications
Support Beyond Olumiant
Those needing affordable specialty medications often also need other affordable medications.
Our list of hundreds of available brand-name medications means patients can access as many medications as they qualify for on our list.
And each medication’s service fee is $70.00 per month, per medication.
Why Choose Prescription Hope for Medication Assistance
Patient-Focused Medication Support
Americans across the nation need support with their prescription costs. They often need to access financial assistance options.
For 20 years, Prescription Hope has advocated on behalf of our patients. We’ve saved our patients a combined hundreds of millions of dollars and supported them with compassion and care.
Simplified Access to Specialty Therapies
Our service fee is $70.00 per month, per medication. Not only do we simplify your application process, but we also continue to handle the administrative tasks long after approval.
Ongoing Prescription Assistance
Our team is dedicated to supporting your ongoing medication assistance throughout your medication access journey. So if you’re looking to apply for the Olumiant patient assistance program and access affordable medications, then be sure to enroll in Prescription Hope today.